AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Relmada Therapeutics Inc (NASDAQ:RLMD)
5.12 USD
-0.080 1.539%News
Loading...
Key Stats
| Previous Close (in USD) | 5.2 |
|---|---|
| Change | -0.080 1.539% |
| 52 W H/L (in USD) | 7.223/2.360 |
| EBITDA (in USD) | -161.248M |
| PE Ratio | -- |
| Volume | 357427 |
| Diluted Eps TTM | -3.13 |
| Total Assets (in USD) | 97.552M |
|---|---|
| Total Liabilities (in USD) | 12.195M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 4.092M |
| Market Cap (in USD) | 92.031 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Sponsored Reports
Loading...
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Relmada Therapeutics Inc
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134
786 629 1376
Employees: 20
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD | CEO & Director | 1960 |
| 2. | Mr. Maged S. Shenouda M.B.A., MBA, R.Ph, R.Ph. | Chief Financial Officer | 1964 |
| 3. | Mr. Charles S. Ence CPA, M.B.A. | Chief Accounting & Compliance Officer | 1965 |
| 4. | Dr. Paolo Manfredi M.D., Ph.D. | Chief Scientific Officer | 1962 |
| 5. | Ms. Gina DiGuglielmo | VP & Head of Clinical Operations | NA |
| 6. | Dr. Marco Pappagallo M.D. | Chief Medical Officer | 1958 |
| 7. | Mr. John Hixon | Head of Commercial | NA |
| 8. | Dr. Richard M. Mangano | Consultant | 1950 |
| 9. | Dr. Sergio Traversa M.B.A., Pharm.D. | CEO & Director | 1960 |
| 10. | Mr. Maged S. Shenouda M.B.A., R.Ph. | Chief Financial Officer | 1964 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.350 2.718% | 49.95 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
0.000 0.000% | 49.25 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+7.090 1.480% | 483.13 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+19.440 2.914% | 676.93 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -157.044M | -125.752M | -59.456M | -17.318M | -8.961M |
| Minority Interest | - | - | - | - | - |
| Net Income | -152.839M | -125.799M | -58.07M | -17.318M | -8.961M |
| Selling General Administrative | 47.926M | 35.082M | 24.866M | 5.703M | 3.975M |
| Gross Profit | - | - | - | - | - |
| Reconciled Depreciation | 0M | 0.001M | 0.004M | - | 0.005M |
| Ebit | -161.249M | -125.703M | -60.839M | -8.899M | -6.209M |
| Ebitda | -156.443M | -124.456M | -60.822M | -8.894M | -6.206M |
| Depreciation And Amortization | 4.806M | 1.247M | 0.017M | 0.005M | 0.003M |
| Operating Income | -161.249M | -125.703M | -60.839M | -12.728M | -6.917M |
| Other Operating Expenses | 161.249M | 125.703M | 60.839M | 12.728M | 6.917M |
| Interest Expense | 4.205M | 0.048M | 1.399M | - | 1.337M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 2.659M | 1.199M | - | - | - |
| Net Interest Income | 2.659M | 1.199M | 1.399M | - | -0.761M |
| Income Tax Expense | -4.205M | 0.047M | -1.386M | -3.829M | 0.63M |
| Total Revenue | 0M | 0M | 0M | - | 0M |
| Total Operating Expenses | 161.249M | 125.703M | 60.839M | 12.728M | 6.917M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 4.205M | -0.048M | 1.382M | -3.829M | -0.707M |
| Net Income From Continuing Ops | -157.044M | -125.752M | -59.456M | - | -17.318M |
| Net Income Applicable To Common Shares | -157.044M | -125.752M | -59.456M | -15.005M | - |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 97.552M | 152.905M | 223.326M | 118.186M | 10.22M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 1.185M | -0M | 0M | -0M | -0M |
| Total Liab | 12.195M | 12.469M | 15.061M | 12.603M | 2.606M |
| Total Stockholder Equity | 85.357M | 140.436M | 208.265M | 105.583M | 7.613M |
| Other Current Liab | 8.689M | 7.207M | 3.868M | 4.257M | -0M |
| Common Stock | 0.03M | 0.03M | 0.028M | 0.016M | 0.039M |
| Capital Stock | 0.03M | 0.03M | 0.028M | 0.016M | - |
| Retained Earnings | -560.903M | -462.111M | -305.067M | -179.315M | -111.662M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.035M | 0.028M | 0.111M | 0.191M |
| Cash | 4.092M | 5.396M | 44.443M | 2.495M | 9.217M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 12.195M | 12.469M | 15.061M | 12.603M | 2.606M |
| Current Deferred Revenue | - | - | - | - | 1.318M |
| Net Debt | -4.092M | -5.396M | -44.443M | -2.495M | -8.852M |
| Short Term Debt | - | - | - | - | 0.364M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | - | - | - | - | 0.364M |
| Other Stockholder Equity | 646.23M | 602.517M | 513.304M | 284.882M | 119.237M |
| Property Plant Equipment | - | - | - | 0.001M | 0.005M |
| Total Current Assets | 97.509M | 152.87M | 223.298M | 118.074M | 9.984M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 92.232M | 142.927M | 167.466M | 114.596M | 80.165M |
| Net Receivables | - | 0.512M | 0.086M | 0.079M | 0.247M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | 4.035M | 11.302M | 0.903M | 0.521M |
| Accounts Payable | 3.506M | 5.262M | 11.193M | 8.346M | 0.924M |
| Accumulated Other Comprehensive Income | - | - | - | - | -0.012M |
| Non Currrent Assets Other | 0.043M | 0.035M | 0.028M | 0.111M | 0.228M |
| Non Current Assets Total | 0.043M | 0.035M | 0.028M | 0.113M | 0.235M |
| Capital Lease Obligations | - | - | - | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 19.734M | -54.118M | -34.448M | -80.165M | -80.165M |
| Total Cashflows From Investing Activities | 19.734M | -54.118M | -34.448M | -80.165M | -160.33M |
| Total Cash From Financing Activities | 45.02M | 187.939M | 28.473M | 17.475M | 6.543M |
| Net Income | -157.044M | -125.752M | -59.456M | -17.318M | -8.961M |
| Change In Cash | -39.048M | 41.948M | -33.783M | 6.978M | 0.528M |
| Begin Period Cash Flow | 44.443M | 2.495M | 36.279M | 2.239M | 1.711M |
| End Period Cash Flow | 5.396M | 44.443M | 2.495M | 9.217M | 2.239M |
| Total Cash From Operating Activities | -103.802M | -91.873M | -27.809M | -10.498M | -6.002M |
| Depreciation | 0M | 0.001M | 0.004M | 0.005M | 0.003M |
| Other Cashflows From Investing Activities | - | - | - | -80.165M | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 42.729M | - | - | 113.895M | 17.761M |
| Other Cashflows From Financing Activities | 1.675M | 2.628M | 8.056M | -0.254M | 6.543M |
| Capital Expenditures | 0M | 0M | 0M | 0M | 0.012M |
| Change In Working Capital | 7.454M | -7.865M | 10.85M | 1.505M | 0.7M |
| Other Non Cash Items | 1.593M | 1.247M | 0.017M | 0.267M | 1.029M |
| Free Cash Flow | -103.802M | -91.873M | -27.809M | -10.498M | -6.014M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 851916 |
| 2. | Franklin Biotechnology Discv A(acc)USD | 2 years ago | 421900 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 353625 |
| 4. | Horizons Psychedelic Stock ETF | 2 years ago | 227040 |
| 5. | Franklin Biotechnology Discovery A | 2 years ago | 205000 |
| 6. | Fidelity Extended Market Index | 2 years ago | 139025 |
| 7. | Bridgeway Ultra-Small Company | 2 years ago | 114877 |
| 8. | Federated Hermes MDT SCG Institutional | 2 years ago | 96010 |
| 9. | Federated Hermes MDT Small Cap Growth IS | 2 years ago | 96010 |
| 10. | AdvisorShares Psychedelics ETF | 2 years ago | 77022 |
| 11. | Bridgeway Ultra-Small Company Market | 2 years ago | 72600 |
| 12. | Fidelity Enhanced Small Cap ETF | 2 years ago | 57801 |
| 13. | iShares Micro-Cap ETF | 2 years ago | 55336 |
| 14. | BlackRock Extended Mkt Composite | 2 years ago | 55209 |
| 15. | BlackRock Extended Equity Market K | 2 years ago | 48183 |
| 16. | Fidelity Total Market Index | 2 years ago | 43595 |
| 17. | Acadian Global Small-Cap Equity CIT Cl A | 2 years ago | 36230 |
| 18. | Fidelity Series Total Market Index | 2 years ago | 32953 |
| 19. | Avantis US Small Cap Equity ETF | 2 years ago | 31692 |
| 20. | Fidelity VIP Disciplined Small Cap Init | 2 years ago | 29525 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 2 years ago | 572743 |
| 2. | Vanguard Group Inc | 2 years ago | 1256705 |
| 3. | Deep Track Capital, LP | 2 years ago | 1240034 |
| 4. | Vestal Point Capital LP | 2 years ago | 1200000 |
| 5. | Acadian Asset Management LLC | 2 years ago | 1181186 |
| 6. | Parsons Capital Management Inc | 2 years ago | 973520 |
| 7. | Opaleye Management Inc | 2 years ago | 759000 |
| 8. | Palo Alto Investors, LLC | 2 years ago | 732400 |
| 9. | Millennium Management LLC | 2 years ago | 341450 |
| 10. | Two Sigma Advisers, LLC | 2 years ago | 326200 |
| 11. | Mirae Asset Global Investments (Korea) Co Ltd | 2 years ago | 270396 |
| 12. | Geode Capital Management, LLC | 2 years ago | 243413 |
| 13. | Two Sigma Investments LLC | 2 years ago | 227039 |
| 14. | Deutsche Bank AG | 2 years ago | 224846 |
| 15. | Guild Investment Management Inc | 2 years ago | 212100 |
| 16. | Bank of America Corp | 2 years ago | 210631 |
| 17. | Marshall Wace Asset Management Ltd | 2 years ago | 207870 |
| 18. | Bridgeway Capital Management, LLC | 2 years ago | 195777 |
| 19. | RBF LLC | 2 years ago | 165474 |
| 20. | Group One Trading, LP | 2 years ago | 158427 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...